List view / Grid view
7 June 2016 | By Victoria White, Digital Content Producer
The primary endpoint primary endpoint was a multicomponent measure evaluating improvement of physical function, cognitive function, and disability...
22 April 2016 | By Victoria White, Digital Content Producer
New data demonstrates daclizumab’s positive cognitive outcomes and safety profile in patients with relapsing-remitting multiple sclerosis (RRMS)...
18 April 2016 | By Victoria White, Digital Content Producer
Biogen has unveiled new Tecfidera research that reinforces its sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis patients...
5 April 2016 | By Victoria White
RedHill has announced encouraging top-line interim results from its CEASE-MS study of RHB-104 in patients with relapsing-remitting multiple sclerosis...
18 February 2016 | By Victoria White
Reductions in brain lesions at week 24 were maintained while relapses were further reduced at week 72 with continuous ozanimod treatment...
17 February 2016 | By Victoria White
Roche's ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis...
18 January 2016 | By Victoria White
Autologous haematopoietic stem cell transplantation (AHSCT), developed at Sheffield Teaching Hospitals, has shown 'remarkable' results in patients with MS...
21 October 2015 | By Victoria White
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis did not achieve its primary and secondary endpoints...
9 October 2015 | By Victoria White
Roche’s Chief Medical Officer said the results of the pivotal trials have the potential to transform the treatment of MS...
8 October 2015 | By Victoria White
Lemtrada targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS...
8 October 2015 | By Victoria White
The analysis evaluated the proportion of Gilenya patients achieving 'no evidence of disease activity' (NEDA-4) every year over seven years...
7 October 2015 | By Victoria White
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024...
7 October 2015 | By Victoria White
Biogen is to present the data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...
7 October 2015 | By Victoria White
MRI data from Genzyme’s Phase III TEMSO study demonstrate that Aubagio significantly slowed brain atrophy in people with relapsing multiple sclerosis (RMS)...
6 August 2015 | By Victoria White
Apitope today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736)...
